Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'EVERY 3 WEEKS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 80 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Zufia, L; Aldaz, A; Giraldez, J
      Separation methods for camptothecin and related compounds

      JOURNAL OF CHROMATOGRAPHY B
    2. Mathijssen, RHJ; van Alphen, RJ; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
      Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)

      CLINICAL CANCER RESEARCH
    3. Kehrer, DFS; Soepenberg, O; Loos, WJ; Verweij, J; Sparreboom, A
      Modulation of camptothecin analogs in the treatment of cancer: a review

      ANTI-CANCER DRUGS
    4. Bernstein, ML; Reaman, GH; Hirschfeld, S
      Developmental therapeutics in childhood cancer - A perspective from the Children's Oncology Group and the US Food and Drug Administration

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    5. Vanhoefer, U; Harstrick, A; Achterrath, W; Cao, SS; Seeber, S; Rustum, YM
      Irinotecan in the treatment of colorectal cancer: Clinical overview

      JOURNAL OF CLINICAL ONCOLOGY
    6. Pratesi, G; Laccabue, D
      BAY 59-8862 - Oncolytic

      DRUGS OF THE FUTURE
    7. Sloan, JA; Atherton, P; Reid, J; Pilot, HC; Erlichman, C; Schaaf, L
      Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    8. Seymour, L; Eisenhauer, E
      A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    9. Jansman, FGA; Sleijfer, DT; de Graaf, JC; Coenen, JLLM; Brouwers, JRBJ
      Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer

      DRUG SAFETY
    10. Wouters, BG; Delahoussaye, YM; Evans, JW; Birrell, GW; Dorie, MJ; Wang, JL; MacDermed, D; Chiu, RK; Brown, JM
      Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine

      CANCER RESEARCH
    11. Firvida, JL; Irigoyen, A; Vazquez-Estevez, S; Diz, P; Constenla, M; Casal-Rubio, J; Valladares-Ayerbes, M; Castellanos, J; Rodriguez, R; Balcells, M
      Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma

      CANCER
    12. Escoriaza, J; Aldaz, A; Castellanos, C; Calvo, E; Giraldez, J
      Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies

      JOURNAL OF CHROMATOGRAPHY B
    13. Denny, WA; Wilson, WR
      Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    14. Ma, MK; Zamboni, WC; Radomski, KM; Furman, WL; Santana, VM; Houghton, PJ; Hanna, SK; Smith, AK; Stewart, CF
      Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan

      CLINICAL CANCER RESEARCH
    15. Gornet, JM; Azoulay, D; Duclos-Vallee, JC; Goldwasser, F
      Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11

      ANTI-CANCER DRUGS
    16. Takimoto, CH; Morrison, G; Harold, N; Quinn, M; Monahan, BP; Band, RA; Cottrell, J; Guemei, A; Llorens, V; Hehman, H; Ismail, AS; Flemming, D; Gosky, DM; Hirota, H; Berger, SJ; Berger, NA; Chen, AP; Shapiro, JD; Arbuck, SG; Wright, J; Hamilton, JM; Allegra, CJ; Grem, JL
      Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    17. Murren, JR; Peccerillo, K; DiStasio, SA; Li, X; Leffert, JJ; Pizzorno, G; Burtness, BA; McKeon, A; Cheng, YC
      Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    18. Ychou, M; Douillard, JY; Rougier, P; Adenis, A; Mousseau, M; Dufour, P; Wendling, JL; Burki, F; Mignard, D; Marty, M
      Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer - An open-label multicenterphase II study

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    19. Jansman, FGA; Sleijfer, DT; Coenen, JLLM; De Graaf, JC; Brouwers, JRBJ
      Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer

      DRUG SAFETY
    20. Rodriguez-Galindo, C; Radomski, K; Stewart, CF; Furman, W; Santana, VM; Houghton, PJ
      Clinical use of topoisomerase I inhibitors in anticancer treatment

      MEDICAL AND PEDIATRIC ONCOLOGY
    21. Aravantinos, G; Skarlos, DV; Kosmidis, P; Georgoulias, V; Sgouros, I; Bafaloukos, D; Androulakis, N; Florou, S; Fountzilas, G
      Irinotecan (CPT-11) in patients with advanced colorectal cancer previouslytreated with 5-fluorouracil-based chemotherapy

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    22. Bleiberg, H
      CPT-11 in gastrointestinal cancer

      EUROPEAN JOURNAL OF CANCER
    23. Loos, WJ; Verweij, J; Gelderblom, HJ; de Jonge, MJA; Brouwer, E; Dallaire, BK; Sparreboom, A
      Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans

      ANTI-CANCER DRUGS
    24. Twelves, C
      UFT plus calcium folinate/irinotecan in colorectal cancer

      ONCOLOGY-NEW YORK
    25. Furman, WL; Stewart, CF; Poquette, CA; Pratt, CB; Santana, VM; Zamboni, WC; Bowman, LC; Ma, MK; Hoffer, FA; Meyer, WH; Pappo, AS; Walter, AW; Houghton, PJ
      Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

      JOURNAL OF CLINICAL ONCOLOGY
    26. Herben, VMM; Schellens, JHM; Swart, M; Gruia, G; Vernillet, L; Beijnen, JH; Huinink, WWT
      Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors

      JOURNAL OF CLINICAL ONCOLOGY
    27. Lhomme, C; Fumoleau, P; Fargeot, P; Krakowski, Y; Dieras, V; Chauvergne, J; Vennin, P; Rebattu, P; Roche, H; Misset, JL; Lentz, MA; Van Glabbeke, M; Matthieu-Boue, A; Mignard, D; Chevallier, B
      Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix

      JOURNAL OF CLINICAL ONCOLOGY
    28. Boku, N; Ohtsu, A; Shimada, Y; Shirao, K; Seki, S; Saito, H; Sakata, Y; Hyodo, I
      Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

      JOURNAL OF CLINICAL ONCOLOGY
    29. Shulman, LN; Buswell, L; Riese, N; Doherty, N; Loeffler, JS; von Roemeling, RW; Coleman, CN
      Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    30. Weitman, S; Mangold, G; Marty, J; Dexter, D; Hilsenbeck, S; Rake, J; Juniewicz, P; Von Hoff, D
      Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    31. Lima, CMSR; Eckardt, JR; Leong, SS; Sherman, CA; Perkel, JA; Putman, T; Safa, AR; Bahadori, HR; Green, MR
      Single-agent gemcitabine and gemcitabine/irinotecan combination (IrimoGem)in non-small cell lung cancer

      SEMINARS IN ONCOLOGY
    32. O'Meara, AT; Sevin, BU
      In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan)

      GYNECOLOGIC ONCOLOGY
    33. Nakano, T; Chahinian, AP; Shinjo, M; Togawa, N; Tonomura, A; Miyake, M; Ninomiya, K; Yamamoto, T; Higashino, K
      Cisplatin in combination with irinotecan in the treatment of patients withmalignant pleural mesothelioma - A pilot phase II clinical trial and pharmacokinetic profile

      CANCER
    34. HERBEN VMM; MAZEE D; VANGORTELVANZOMEREN DM; ZEEDIJK S; ROSING H; SCHELLENS JHM; HUININK WWT; BEIJNEN JH
      SENSITIVE DETERMINATION OF THE CARBOXYLATE AND LACTONE FORMS OF THE NOVEL ANTITUMOR DRUG IRINOTECAN AND ITS ACTIVE METABOLITE IN PLASMA BY HPLC

      Journal of liquid chromatography & related technologies
    35. SPARREBOOM A; DEJONGE MJA; DEBRUIJN P; BROUWER E; NOOTER K; LOOS WJ; VANALPHEN RJ; MATHIJSSEN RHJ; STOTER G; VERWEIJ J
      IRINOTECAN (CPT-11) METABOLISM AND DISPOSITION IN CANCER-PATIENTS

      Clinical cancer research
    36. Cersosimo, RJ
      Irinotecan: A new antineoplastic agent for the management of colorectal cancer

      ANNALS OF PHARMACOTHERAPY
    37. OLEARY J; MUGGIA FM
      CAMPTOTHECINS - A REVIEW OF THEIR DEVELOPMENT AND SCHEDULES OF ADMINISTRATION

      European journal of cancer
    38. HERBEN VMM; HUININK WWT; SCHELLENS JHM; BEIJNEN JH
      CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS

      Pharmacy world & science
    39. BOZEC L; BIERLING P; FROMONT P; LEVI F; DEBAT P; CVITKOVIC E; MISSET JL
      IRINOTECAN-INDUCED IMMUNE THROMBOCYTOPENIA

      Annals of oncology
    40. ECKHARDT SG
      IRINOTECAN - A REVIEW OF THE INITIAL PHASE-I TRIALS

      Oncology
    41. PITOT HC
      US PIVOTAL STUDIES OF IRINOTECAN IN COLORECTAL-CARCINOMA

      Oncology
    42. SALTZ LB
      IRINOTECAN IN THE FIRST-LINE TREATMENT OF COLORECTAL-CANCER

      Oncology
    43. ROSEN LS
      IRINOTECAN IN LYMPHOMA, LEUKEMIA, AND BREAST, PANCREATIC, OVARIAN, AND SMALL-CELL LUNG CANCERS

      Oncology
    44. WADLER S; BENSON AB; ENGELKING C; CATALANO R; FIELD M; KORNBLAU SM; MITCHELL E; RUBIN J; TROTTA P; VOKES E
      RECOMMENDED GUIDELINES FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED DIARRHEA

      Journal of clinical oncology
    45. SALIBA F; HAGIPANTELLI R; MISSET JL; BASTIAN G; VASSAL G; BONNAY M; HERAIT P; COTE C; MAHJOUBI M; MIGNARD D; CVITKOVIC E
      PATHOPHYSIOLOGY AND THERAPY OF IRINOTECAN-INDUCED DELAYED-ONSET DIARRHEA IN PATIENTS WITH ADVANCED COLORECTAL-CANCER - A PROSPECTIVE ASSESSMENT

      Journal of clinical oncology
    46. IYER L; RATAIN MJ
      CLINICAL-PHARMACOLOGY OF CAMPTOTHECINS

      Cancer chemotherapy and pharmacology
    47. TAKIMOTO CH; WRIGHT J; ARBUCK SG
      CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS

      Biochimica et biophysica acta, N. Gene structure and expression
    48. THOMPSON J; STEWART CF; HOUGHTON PJ
      ANIMAL-MODELS FOR STUDYING THE ACTION OF TOPOISOMERASE-I TARGETED DRUGS

      Biochimica et biophysica acta, N. Gene structure and expression
    49. SIU LL; ROWINSKY EK
      A RISK-BENEFIT ASSESSMENT OF IRINOTECAN IN SOLID TUMORS

      Drug safety
    50. ROTHENBERG ML
      EFFICACY AND TOXICITY OF IRINOTECAN IN PATIENTS WITH COLORECTAL-CANCER

      Seminars in oncology
    51. ARBUCK SG; TAKIMOTO CH
      AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS

      Seminars in hematology
    52. ABANG AM
      THE CLINICAL-PHARMACOLOGY OF TOPOISOMERASE-I INHIBITORS

      Seminars in hematology
    53. ROBERT J; RIVORY L
      PHARMACOLOGY OF IRINOTECAN

      Medicamentos de actualidad
    54. SAIJO N
      NEW CHEMOTHERAPEUTIC-AGENTS FOR THE TREATMENT OF NONSMALL CELL LUNG-CANCER - THE JAPANESE EXPERIENCE

      Chest
    55. PUNT CJA
      NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA

      Cancer
    56. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    57. Cottu, PH; Extra, JM; Lerebours, F; Espie, M; Marty, M
      Clinical activity of irinotecan

      BULLETIN DU CANCER
    58. Boige, V; Raymond, E; Armand, JP
      Irinotecan: drug schedule, research of combinations, and phase I experiences

      BULLETIN DU CANCER
    59. CAI QY; LINDSEY R; ZHANG RW
      REGRESSION OF HUMAN COLON-CANCER XENOGRAFTS IN SCID MICE FOLLOWING ORAL-ADMINISTRATION OF WATER-INSOLUBLE CAMPTOTHECINS

      International journal of oncology
    60. ROTHENBERG ML
      TOPOISOMERASE-I INHIBITORS - REVIEW AND UPDATE

      Annals of oncology
    61. OREILLY S; ROWINSKY EK
      EXPERIMENTAL CHEMOTHERAPEUTIC-AGENTS FOR THE TREATMENT OF COLORECTAL-CARCINOMA

      Hematology/oncology clinics of North America
    62. PITOT HC; WENDER DB; OCONNELL MJ; SCHROEDER G; GOLDBERG RM; RUBIN J; MAILLIARD JA; KNOST JA; GHOSH C; KIRSCHLING RJ; LEVITT R; WINDSCHITL HE
      PHASE-II TRIAL OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA

      Journal of clinical oncology
    63. GUPTA E; MICK R; RAMIREZ J; WANG XL; LESTINGI TM; VOKES EE; RATAIN MJ
      PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF THE TOPOISOMERASE INHIBITOR IRINOTECAN IN CANCER-PATIENTS

      Journal of clinical oncology
    64. SHIRAO K; SHIMADA Y; KONDO H; SAITO D; YAMAO T; ONO H; YOKOYAMA T; FUKUDA H; OKA M; WATANABE Y; OHTSU A; BOKU N; FUJII T; ODA Y; MURO K; YOSHIDA S
      PHASE I-II STUDY OF IRINOTECAN HYDROCHLORIDE COMBINED WITH CISPLATIN IN PATIENTS WITH ADVANCED GASTRIC-CANCER

      Journal of clinical oncology
    65. CREEMERS GJ; GERRITS CJH; ECKARDT JR; SCHELLENS JHM; BURRIS HA; PLANTING AST; RODRIGUEZ GI; LOOS WJ; HUDSON I; BROOM C; VERWEIJ J; VONHOFF DD
      PHASE-I AND PHARMACOLOGICAL STUDY OF ORAL TOPOTECAN ADMINISTERED TWICE-DAILY FOR 21 DAYS TO ADULT PATIENTS WITH SOLID TUMORS

      Journal of clinical oncology
    66. ROUGIER P; BUGAT R; DOUILLARD JY; CULINE S; SUC E; BRUNET P; BECOUARN Y; YCHOU M; MARTY M; EXTRA JM; BONNETERRE J; ADENIS A; SEITZ JF; GANEM G; NAMER M; CONROY T; NEGRIER S; MERROUCHE Y; BURKI F; MOUSSEAU M; HERAIT P; MAHJOUBI M
      PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY

      Journal of clinical oncology
    67. TAKAHASHI T; FUJIWARA Y; SUMIYOSHI H; ISOBE T; YAMAOKA N; YAMAKIDO M
      SALIVARY DRUG-MONITORING OF IRINOTECAN AND ITS ACTIVE METABOLITE IN CANCER-PATIENTS

      Cancer chemotherapy and pharmacology
    68. STEWART CF; ZAMBONI WC; CROM WR; HOUGHTON PJ
      DISPOSITION OF IRINOTECAN AND SN-38 FOLLOWING ORAL AND INTRAVENOUS IRINOTECAN DOSING IN MICE

      Cancer chemotherapy and pharmacology
    69. CHABOT GG
      CLINICAL PHARMACOKINETICS OF IRINOTECAN

      Clinical pharmacokinetics
    70. CASCINU S; DELFERRO E; LIGI M; GIORDANI P
      THE TREATMENT OF ADVANCED COLORECTAL-CARC INOMA - A POSSIBLE CHALLENGE

      Tumori
    71. ALBIN N; MASSADE L; GOUYETTE A
      USE AND APPLICATIONS OF PHARMACOGENETICS IN ONCOLOGY AND HEMATOLOGY

      Bulletin du cancer
    72. MASUDA N; KUDOH S; FUKUOKA M
      IRINOTECAN (CPT-11) - PHARMACOLOGY AND CLINICAL-APPLICATIONS

      Critical reviews in oncology/hematology
    73. OREILLY S; ROWINSKY EK
      THE CLINICAL STATUS OF IRINOTECAN (CPT-11), A NOVEL WATER-SOLUBLE CAMPTOTHECIN ANALOG - 1996

      Critical reviews in oncology/hematology
    74. SHIMADA Y; ROUGIER P; PITOT H
      EFFICACY OF CPT-11 (IRINOTECAN) AS A SINGLE-AGENT IN METASTATIC COLORECTAL-CANCER

      European journal of cancer
    75. BLEIBERG H; CVITKOVIC E
      CHARACTERIZATION AND CLINICAL MANAGEMENT OF CPT-11 (IRINOTECAN)-INDUCED ADVERSE EVENTS - THE EUROPEAN PERSPECTIVE

      European journal of cancer
    76. ARMAND JP; EXTRA YM; CATIMEL G; ABIGERGES D; MARTY M; CLAVEL M
      RATIONALE FOR THE DOSAGE AND SCHEDULE OF CPT-11 (IRINOTECAN) SELECTEDFOR PHASE-II STUDIES, AS DETERMINED BY EUROPEAN PHASE-I STUDIES

      Annals of oncology
    77. DENT SF; EISENHAUER EA
      PHASE-I TRIAL DESIGN - ARE NEW METHODOLOGIES BEING PUT INTO PRACTICE

      Annals of oncology
    78. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
      PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER

      Journal of clinical oncology
    79. STEWART CF; ZAMBONI WC; CROM WR; GAJJAR A; HEIDEMAN RL; FURMAN WL; MEYER WH; HOUGHTON PJ; PRATT CB
      TOPOISOMERASE-I INTERACTIVE DRUGS IN CHILDREN WITH CANCER

      Investigational new drugs
    80. WISEMAN LR; MARKHAM A
      IRINOTECAN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN THE MANAGEMENT OF ADVANCED COLORECTAL-CANCER

      Drugs


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/10/20 alle ore 00:25:21